Compare Firy Inc. (FIRY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Summit Therapeutics Inc — how do they compare? Firy Inc. trades at $12.07 (market cap $199.80M), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 68.6× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Summit Therapeutics Inc for 16 Days on average.
| FIRY | SMMT | |
|---|---|---|
Market Cap | $199.80M | $13.71B |
Volume | 92,993 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $13.10 | $26.38 |
52-Week Low | $2.28 | $12.43 |
Typical Hold Time | 13 Days | 16 Days |
Enterprise Value | $168.40M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.07, up 1.86% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but a net loss, continuing a trend of negative profitability. Recent developments include a major legal victory with a $719 million judgment and the appointment of Marc Lasry to the board, signaling strategic shifts under its new holding company structure.
The outlook remains challenged by persistent cash burn and negative margins, though the legal win offers potential upside. Risks include high cash outflow and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, reflecting uncertainty around the company's path to profitability.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
